4D Molecular Therapeutics CEO sells 58,061 shares

The company's president and chief executive reported sales under a Rule 10b5-1 plan adopted January 9, 2026.

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. President and Chief Executive Officer David Kirn reported two direct sales of Common Stock on October 5, 2026: 58,061 shares at a weighted average sale price of $12.9215 per share, and 272 shares at a weighted average sale price of $13.6104 per share.

Both sales were made under a Rule 10b5-1 trading plan adopted January 9, 2026. The 58,061-share sale was executed at prices from $12.61 to $13.60, and the 272-share sale at prices from $13.61 to $13.63.

Insider Trade Summary 10b5-1

Net Seller: 58,333 shares

Net Sell 2 txns

Insider Kirn David

Role See Remarks

Sold 58,333 shs ($754K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	58,061	$12.9215	$750K
Sale	Common Stock F1, F3	272	$13.6104	$4K

Holdings After Transaction: Common Stock — 709,153 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
2. F2. The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 58,061 shares Weighted average sale price: $12.9215 per share Execution price range: $12.61 to $13.60 per share +3 more

6 metrics

Shares sold 58,061 shares October 5, 2026 sale

Weighted average sale price $12.9215 per share 58,061-share sale

Execution price range $12.61 to $13.60 per share 58,061-share sale

Shares sold 272 shares October 5, 2026 sale

Weighted average sale price $13.6104 per share 272-share sale

Execution price range $13.61 to $13.63 per share 272-share sale

Key Terms

10b5-1 trading plan, weighted average sale price, direct ownership

3 terms

10b5-1 trading plan financial

"Transaction made pursuant to a 10b5-1 trading plan"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

weighted average sale price financial

"reflects the weighted average sale price"

direct ownership financial

"Common Stock reported as held directly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FDMT shares did the president and chief executive sell, and at what prices?

David Kirn reported selling 58,061 shares at a weighted average of $12.9215 per share and 272 shares at a weighted average of $13.6104 per share on October 5, 2026. The respective execution price ranges were $12.61 to $13.60 and $13.61 to $13.63; both sales were under a Rule 10b5-1 plan adopted January 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 05:12 PM Accepted by SEC EDGAR 10/07/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirn David

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		S(1)		58,061	D	$12.9215(2)	709,425	D
Common Stock	10/05/2026		S(1)		272	D	$13.6104(3)	709,153	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

2. The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President and Chief Executive Officer

	/s/ Scott Bizily as Attorney-in-Fact for David Kirn	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)